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Abstract 
Background: Anxiety is common in youth on the autism spectrum and cognitive behavioural therapy (CBT) has 
been adapted to address associated symptoms. The aim of the current systematic review and meta-analysis was to 
examine the efficacy of CBT for reducing anxiety in autistic youth.
Method: Searches of PubMed and Scopus databases were undertaken from January 1990 until December 2020. 
Studies were included if they consisted of randomised controlled trials (RCTs) using CBT to reduce anxiety in autistic 
youth. Separate random effects meta-analyses assessed anxiety ratings according to informant (clinician; parent; 
child), both at end-of-trial and at follow-up.
Results: A total of 19 RCTs met our inclusion criteria (833 participants: CBT N = 487; controls N = 346). Random 
effects meta-analyses revealed a large effect size for clinician rated symptoms (g = 0.88, 95% CI 0.55, 1.12, k = 11), 
while those for both parent (g = 0.40, 95% CI 0.24, 0.56; k = 18) and child-reported anxiety (g = 0.25, 95% CI 0.06, 0.43; 
k = 13) were smaller, but significant. These benefits were not however maintained at follow-up. Moderator analyses 
showed that CBT was more efficacious for younger children (for clinician and parent ratings) and when delivered as 
individual therapy (for clinician ratings). Using the Cochrane Risk of Bias 2 tool, we found concerns about reporting 
bias across most trials.
Conclusions: The efficacy of CBT for anxiety in autistic youth was supported in the immediate intervention period. 
However, substantial inconsistency emerged in the magnitude of benefit depending upon who was rating symptoms 
(clinician, parent or child). Follow-up analyses failed to reveal sustained benefits, though few studies have included 
this data. It will be important for future trials to address robustness of treatment gains overtime and to further explore 
inconsistency in efficacy by informant. We also recommend pre-registration of methods by trialists to address con-
cerns with reporting bias.
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Background
Autism Spectrum Disorder (ASD) is a lifelong, neurode-
velopmental condition characterised by difficulties in 
social interaction, social communication and restricted 
and/or repetitive patterns of behaviour [1]. As many as 
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70% of autistic people have at least one co-occurring 
mental health condition [2]. Studies consistently indicate 
a disproportionate risk of anxiety and anxiety-disorders 
in particular, though prevalence estimates vary consider-
ably [2–4]. In their meta-analysis, Van Steensel et al. [3] 
reported a pooled prevalence of 39.6% of autistic youth 
aged under 18  years meeting criteria for at least one 
anxiety disorder aligned to the Diagnostic and Statistical 
Manual of Mental Health Disorders (DSM-IV) [5]. White 
et  al. [4] propose that between 11 and 84% of autistic 
youth experience symptoms that have some degree of 
impact on functioning. Looking at all age groups, Lai 
et al. [2] suggest that 20% of people on the autism spec-
trum meet criteria for a co-occurring anxiety disorder. 
Variability in estimates are likely to reflect heterogene-
ity in study design and study quality [6–8]. Nevertheless, 
available evidence emphasises that anxiety disorders are 
far more common in autistic people than in the general 
population [9, 10]. This highlights the need for effective 
assessment and targeted intervention as part of routine 
clinical care.
Cognitive behavioural therapy (CBT) has been 
advanced as an effective, evidence-based intervention 
for anxiety [11–13]. This includes when delivered in 
adapted formats such as briefer treatment protocols [14] 
and e-health [15, 16]. In the United Kingdom (UK), the 
National Institute for Health and Care Excellence (NICE) 
endorses CBT as the first line of treatment for various 
mental health conditions, including anxiety in youth [17]. 
CBT is a short-term, talk based therapy that focuses on 
the interconnection of thoughts, feelings and behaviour. 
The core components of treatment protocols include 
psychoeducation, cognitive restructuring (i.e. identifying 
and challenging maladaptive thinking), mindfulness tech-
niques, and graded exposure [18]. Across general popu-
lations, the efficacy of CBT for reducing symptoms of 
anxiety has been demonstrated; and includes the main-
tenance of treatment gains for up to 12 months amongst 
youth receiving CBT for anxiety disorders [19, 20].
The past decade has seen significant interest in the 
adaption of CBT for autistic children and adolescents. 
Intuitively, several factors might suggest that CBT may 
not be suited to this context. For example, treatment 
protocols often require consideration of multiple pos-
sibilities such as different causes or outcomes in  situ-
ations. Restricted behavioural and cognitive profiles 
associated with ASD might therefore be expected to 
interfere with treatment engagement [22]. CBT also 
requires individuals to be able to attend to internal sig-
nals such as sensations and emotions. Both interocep-
tive [23] and introspective [24] abilities are impacted in 
ASD and may further compromise treatment efficacy. 
Withstanding such challenges, it has been argued that 
with suitable adaptation, CBT may work well for autis-
tic youth. Spain and Happé [25] summarise that the 
structured nature of CBT, in-depth and collaborative 
focus on issues, alongside attention to graded exposure 
to practice application of skills are advantageous.
An emerging body of evidence supports the use of 
adapted CBT protocols for autistic youth [26–31], 
including across individual [26, 27], group [29, 30], 
parent-mediated [31], as well as online modalities 
[28]. Lang et  al. [32] described important modifica-
tions to treatment protocols. They state that adapta-
tion is less contingent on abilities such as introspection 
and emphasise the need for a more practical focus that 
prioritises behavioural over cognitive mechanisms for 
change. More recently, drawing on the views of prac-
titioners and trialists, modifications were categorised 
under three areas: additions to treatment protocols to 
better accommodate the needs of autistic people (e.g. 
allowing clients not to make eye contact), leaving things 
out, (e.g. focus on core beliefs) and modifying conven-
tional practice (e.g. diversifying communication tech-
niques) [25]. With such adaptions, autistic youth can 
be supported in developing a good therapeutic alliance, 
which is important to facilitate behavioural change 
[33].
In a recent meta-analytic review, Perihan et  al. [34] 
concluded that CBT has a moderate effect (g = − 0.66) 
on the reduction of anxiety in autistic youth aged under 
18  years. The researchers also highlighted impor-
tant moderators of treatment gains. Specifically, par-
ent involvement and longer treatment protocols were 
found to advance more benefit. Although Perihan et  al. 
is the most current evidence synthesis, its conclusions 
are limited by the inclusion of 7 out of 24 samples (30%) 
being from non-randomised studies. Whilst it is useful 
to summarise all available evidence, in meta-analysis, 
this requires consideration of study design features and 
adjustment of estimates of effect sizes [35]. Further, the 
pooling of both between-group comparisons of CBT 
versus controls with pre-post effect sizes within CBT 
groups and the pooling of anxiety measures within tri-
als (i.e. where multiple informant measures were taken) 
is also problematic. An earlier meta-analysis, Ung et  al. 
[36] reported a mean effect size of 0.71 although this 
reduced to 0.47 with the exclusion of one extreme outlier 
study. More crucially, like Perihan et  al., Ung et  al. also 
included non-randomised samples (2/14 studies) and 
pooled data across informants (self, parent and clinician). 
This could mask important discrepancies that impact the 
overall judgement of clinical efficacy. It is recognised that 
children and young people frequently differ in reporting 
symptom experience as compared to parents and clini-
cians [37].
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The importance of analysing informants separately was 
highlighted by the meta-analysis of Sukhodolsky et  al. 
[38]. They analysed raters separately, with effect sizes of 
1.21, 1.19 and 0.68 for clinicians (k = 5), parents (k = 6) 
and child (k = 5) respectively. These effect sizes were 
reduced with the removal of one extreme outlier in each 
analysis to 0.89, 0.57 and 0.17 respectively. While the data 
from Sukhodolsky and colleagues points to some large 
discrepancies, the number of trials included was small. 
It is therefore unclear from existing evidence syntheses 
whether or not the informant impacts perceptions of 
CBT efficacy. Previous evidence reviews [34, 36, 38] have 
also not attended to whether the impact of CBT is sus-
tained at follow-up, an important limitation of research 
into therapeutic benefit more generally [21]. To over-
come these issues, the current study aimed to system-
atically review and meta-analyse the published literature 
on CBT in ASD derived from RCT’s assessing different 
informant ratings (clinician, parent and child) of anxiety 
symptoms both at end of trial and at follow-up.
Methods
Search strategy
This review adhered to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) rec-
ommendations [39] (see Additional File 1). Searches were 
conducted using the electronic databases Scopus and 
Pubmed for relevant trials using the following combina-
tion of search terms: (asperger OR autism OR “pervasive 
developmental disorder”) AND (anxiety OR anxi*) AND 
(“cognitive behavio*” OR CBT). Titles, abstracts and 
keywords were searched in Scopus, and all fields were 
searched in Pubmed. Lateral search techniques were 
used such as hand searching the references of papers for 
related articles and using Google Scholar to carryout key 
word searches. All databases were searched for all years 
from January 1990 to December 2020. The review was 
not pre-registered.
Selection of studies
One reviewer (TM) screened the titles and abstracts of 
all retrieved studies to determine suitability for inclu-
sion in the review using the following criteria: (1) par-
ticipants were aged up to 18 years, (2) participants had a 
diagnosis of ASD according to DSM or ICD criteria, (3) 
participants were diagnosed with co-occurring anxiety 
disorder, (4) study was an RCT design, (5) intervention 
programme was based on CBT intended for anxiety, (6) 
primary outcome was a standardised measure of anxi-
ety for which baseline and post treatment scores were 
reported (and follow-up where available), (7) study was 
published in a peer reviewed journal, and (8) article was 
published in the English language. The full texts of all 
eligible studies were screened by two reviewers (TM and 
AH). A random sample of 10% of excluded records were 
also checked (SS).
Data extraction
Excel-based data extraction tables were used to record 
information for each study in the meta-analyses. This 
template included: sample size, number of participants in 
each group, type of control condition (e.g. waitlist, treat-
ment as usual), co-morbid diagnoses, study design, set-
ting, blind rating of symptoms and measure of anxiety. 
Participant characteristics extracted included mean age, 
gender distribution and diagnosis. For treatment char-
acteristics, the CBT intervention programme, methods 
of therapy used (e.g. group, individual, parent involve-
ment) and treatment duration were extracted. Data were 
extracted by TM and checked by AH—where any dis-
crepancies occurred, these were checked and discussed 
by the whole research team.
Statistical analysis
The effect size employed was Hedges g, which is the 
standardised difference between means, corrected for 
the tendency towards overestimation in small studies. 
Separate analyses were conducted for parent, clinician 
and child reported anxiety measures. All data analysis 
was conducted using Comprehensive Meta-Analysis Ver-
sion 2.0 (http:// www. meta- analy sis. com/) using random 
effects models. Effect sizes were calculated using the 
post treatment scores derived separately (where possi-
ble) for anxiety ratings given by: parents, clinicians and 
the children themselves. Effect sizes were described using 
Cohen’s convention, where an effect size of 0.20 is con-
sidered small, 0.50 is moderate, and 0.80 is large. Publica-
tion bias was assessed by examining funnel plots, using 
the Duvall and Tweedie Trim and Fill method [40].
In cases where trials had multiple intervention groups 
and only one control group [41, 42], we followed 
Cochrane handbook guidance [43], and halved the con-
trol sample size when calculating effect sizes (to avoid 
double counting and thus influencing their weighting in 
analyses). If studies involved resampling or enlarging of 
samples in earlier studies, we would extract data from the 
largest study only (though this situation did not arise).
Statistical heterogeneity was assessed using the  I2 test, 
with interpretation as follows: 0–40% as might not be 
important; 30–60% as may represent moderate heteroge-
neity; 50–90% may represent substantial heterogeneity; 
75–100% representing considerable heterogeneity. Each 
study was assessed for risk of bias using the Cochrane 
risk of bias tool version 2.0 (RoB2) [44]. The RoB2 
assesses bias that may arise across five domains: bias 
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from randomisation, deviations from intended interven-
tions, missing outcome data, outcome measurement and 
bias in selection of the reported results.
Although no definitive minimum number of studies 
is required for meta-regression, we follow the Cochrane 
Handbook recommendation of 10 studies for a continu-
ous variable [43]; and for a categorical subgroup variable, 
a minimum of 4 studies per group [45].
Moderator analyses were conducted to investigate the 
impact of key trial and participant variables on outcome 
effect sizes, while continuous variables were assessed 
using meta-regression. Moderators were selected based 
on attributes that were deemed as important contribu-
tors to treatment efficacy, for example, treatment dura-
tion [34].
Results
A total of 965 studies were identified from the searches, 
of which 19 RCTs were eligible for inclusion in the 
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Fig. 1 PRISMA flow diagram
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intervention group to a control group (wait list control, 
treatment as usual or active control e.g. counselling).
Narrative synthesis
A summary of study characteristics is provided in 
Table 1. Nineteen studies were included with data from 
833 participants (total intervention group participants 
N = 487; total control group participants N = 346). Sam-
ple sizes for intervention groups ranged from 12 to 66 
and for control groups ranged from 10 to 31 partici-
pants across studies. None of the 19 studies reported on 
adverse events or harms.
The number of CBT treatment sessions ranged 
between 5 and 20, with 16 sessions being the modal num-
ber—typically occurring on a weekly basis. Nine stud-
ies used group CBT, 8 used individual CBT and 2 had a 
combination of group and individual sessions (Additional 
file 2).
The majority of studies used an adapted version of 
CBT for autistic youth. Commonly used CBT interven-
tions included: Behavioural Interventions for Anxiety in 
Children with Autism (BIACA) (k = 4), Exploring Feel-
ings (k = 3), Coping Cat (k = 2) and Cool Kids (k = 2). A 
summary of our inclusion criteria and implemented CBT 
interventions for included studies is given within the 
Additional file 2.
The most commonly used parent and child report 
measures of anxiety were the Spence Children’s Anxiety 
Scale-Parent [57] and Child [58] versions (k = 9) and for 
clinicians, either the Anxiety Disorders Interview Sched-
ule [59] (k = 8) or the Paediatric Anxiety Rating Scale [60] 
(k = 5). A range of other scales were also adopted notably 
for parent and child rated anxiety. We pooled and aver-
aged effect sizes for studies where more than one meas-
ure was used by an informant.
Parent rated
Nineteen studies (20 samples) compared CBT with a 
control group using parent-rated measures of anxiety. 
One study used two parent-rated measures [52] and so 
reported outcomes from the measures for these stud-
ies were combined. Additionally, two studies included 
two interventions compared to one control group [41, 
42]—this was dealt with by halving the size of the control 
group and making comparisons with each intervention 
group separately.
Parent reported outcomes for anxiety in autistic youth 
showed CBT as an efficacious treatment in comparison 
to control conditions. Using a random effects model, 
the overall pooled effect size was medium (g = 0.55 
[95% CI 0.26–0.84]). The studies were heterogeneous 
[Q(18) = 74.55, p < 0.001], with an I2 value of 75.86. How-
ever, one study [46] (g = 4.34) was an outlier showing 
no overlap of 95% CI with any other studies—this same 
study by Chalfant et  al. was also excluded by previous 
meta-analyses [34, 36, 38]. Sensitivity analysis was used 
to explore the effect of this on the model by removing 
this outlier. Removing this study from the model reduced 
the overall Hedge’s g effect size to 0.40 [95% CI 0.24–
0.56], showing that CBT remains efficacious at reducing 
anxiety compared with controls (see Fig. 2). Heterogene-
ity also greatly reduced [Q (17) = 22.03, p = 0.018], with 
an I2 value of 22.84.
Observation of funnel plots and the Trim and fill 
analysis suggested the possibility of one potentially 
missing trial reducing the effect size (g = 0.36, [95% CI 
0.19–0.54]).
Follow‑up
Nine trials (10 samples) contained follow-up data, but 
only 5 samples presented follow-up data for the con-
trols [41, 53–55]. A random effects meta-analysis iden-
tified no significant reduction of anxiety at follow-up 
(g = 0.50 [95% CI − 0.10 to 1.12]). Heterogeneity was high 
[Q(4) = 14.8, p = 0.32; I2 = 72.98].
Clinician rated
Ten studies (11 samples) compared CBT with a control 
group using clinician-rated measures. Three of the stud-
ies used two clinician-rated measures [26, 27, 52] and so 
effect sizes for reported outcomes from the measures for 
these studies were pooled.
Clinician reported outcomes for anxiety in autistic 
youth showed CBT as an efficacious treatment in com-
parison to control conditions for reducing symptoms of 
anxiety. Using a random effects model, the overall pooled 
effect size was large, g = 0.88, 95% CI 0.55–1.21. The stud-
ies were heterogeneous, (Q(10) = 26.74, p < 0.001), with 
an I2 value of 62.61 (see Fig. 3).
Examination of funnel plots and Trim and Fill analysis 
revealed no evidence of publication bias.
Follow‑up
Six trials provided follow up data, but only one had 
follow-up data for controls [55] so no analysis was 
conducted.
Child/young person self rated
Thirteen studies included in the meta-analysis compared 
CBT with a control group using child-rated measures of 
anxiety. One of the studies used two child-rated meas-
ures [46] and so reported outcomes from the measures 
for these studies were combined.
Using a random effects model, the overall pooled effect 
size was g = 0.47 (95% CI − 0.02 to 0.93). The studies were 
heterogeneous, (Q(12) = 78.77, p < 0.001), with an I2 value 
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of 84.76. One study [46] (g = 2.93) was an extreme out-
lier owing to the much larger effect size, whose confi-
dence intervals failed to overlap with any other included 
trials. Sensitivity analysis was used to explore the effect 
of this on the model by removing this outlier. Remov-
ing this study from the model reduced the heterogene-
ity [Q(11) = 10.43, p = 0.49], with an I2 = 0.00 and the 
effect size although it remained significant (g = 0.25 [95% 
CI 0.06–0.43]) (see Fig. 4). Inspection of funnel plots and 
trim and fill analysis revealed no missing studies.
Follow‑up
Seven trials provided follow-up data, but only three pro-
vided follow-up data for controls [48, 53, 54]. A random 
effects meta-analysis on these trials indicated no signifi-
cant benefit of CBT (g = 0.12, [95% CI − 0.23 to 0.47]). 
Heterogeneity was low (Q(2) = 0.67, p = 0.71; I2 = 0%).
Moderator analyses
Four continuous variables (age, year of publication, pro-
portion of male participants, number of sessions and 
proportion of participants with Asperger’s Syndrome) 
were examined as moderators using meta-regression 
analyses (see Table  2). All meta-regression analyses 
were conducted using a Method of Moments approach. 
These analyses revealed that the only significant modera-
tor for effect sizes was age (for parent and clinician rat-
ings), indicating that trials produced larger effect sizes in 
younger children. The failure to find any effect of number 
of sessions may well reflect the fact that the majority of 
trials have used 16 sessions. Similarly, the proportion of 
males per trial showed little variation, with most trials 
being male-dominated.
As effect sizes for clinicians, parents and child ratings 
differed substantially in the analyses outlined above, we 
performed a subgroup analysis comparing effect sizes 
in 6 trials where all three types of ratings were adminis-
tered in the same groups of children [26, 27, 41, 47, 49, 
50]. The pattern of effect sizes was comparable to the 
larger analyses, although this smaller analysis identified 
a much larger effect size for clinicians (1.71 [0.66–1.69]), 
slightly larger for parents (g = 0.58 [0.24–0.91]); however, 
self-ratings were non-significant and comparable to those 
obtained in the larger set (g = 0.26 [− 0.01 to 0.53]). Cli-
nician ratings were significantly greater than child rat-
ings (Q = 9.5 [df = 1], p = 0.002) and just failed to reach 
significance when compared to parental ratings (Q = 3.59 
[df = 1], p = 0.06); while child and parental ratings did not 
significantly differ (Q = 2.12 [df = 1], p = 0.15).
We also used subgroup analysis to compare group ver-
sus individual format therapies for each rating informant. 
Clinician rating for group and individual formats (g 
=  0.53 [0.07–0.99], k = 2) versus g =  1.16 [0.74–1.58], 
k = 7) identified a significantly larger effects for individ-
ual therapy (Q = 5.58, df = 1, p = 0.04). Parent ratings for 
group versus individual formats (g =  0.33 [0.07–0.59]; 
k = 7) vs g = 0.50 [0.33–0.67]; k = 9) did not differ signifi-
cantly (Q = 1.17, df = 1, p = 0.28); nor did child ratings for 
group versus individual (g = 0.32 [0.04–0.60]; k = 6) ver-
sus (g =  0.06 [.− 0.28 to 0.39]; k = 4) differ significantly 
(Q = 1.42, df = 1, p = 0.23).
Earlier trials, using different diagnostic criteria tended 
to also include a number of children who were given a 
diagnosis of Pervasive Developmental Disorder-Not Oth-
erwise Specified (PDD-NOS): Wood et  al. [47] (85%); 
Sung et  al. [48] (83%); Reaven et  al. [30] (6%); McNally 
et al. [49] (5%); Storch et al. [27] (41%); White et al. [50] 
(13%); Storch et  al. [52] (40%); Wood et  al. [26] (43%). 
Because PDD-NOS was diagnosed in a minority of tri-
als, we conducted sub-group analyses comparing effect 
sizes in trials with PDD-NOS diagnoses (k = 8) vs those 
without (k = 11). This revealed no difference in effect 
sizes for ratings by clinicians (Q = 1.03, p = 0.31), par-
ents (Q = 1.75, p = 0.19) or children themselves (Q = 1.32, 
p = 0.25).
We intended to analyse the categorical impact of blind 
versus non-blind outcome assessment. Of course, both 
parents and children/young people were aware of assign-
ment and so non-blind. By contrast, all clinician ratings 
appeared to be blind at outcome and thus we could not 
analyse as a moderator within any rating type.
Risk of bias
All trials were evaluated for risk of bias using the 
Cochrane Risk of Bias Tool (RoB2) [38] by two authors 
(DG & KL). Of the 19 trials, 4/19 (21%) were at low risk 
of bias, 12/19 (63%) some concerns and 3/19 (16%) were 
at high risk of bias. The main area of concern was ‘report-
ing bias’, with only 7/19 (37%) registering their protocol 
(see Table 3).
Discussion
This systematic review and meta-analysis aimed to 
assess the evidence base on the efficacy of CBT in reduc-
ing anxiety in children and young people on the autism 
spectrum. We included data derived only from RCTs 
and considered treatment efficacy from the perspective 
of multiple informants including parent, clinician and 
child/ self-report. Importantly, we also summarised what 
is known about the durability of treatment gains. This has 
been missing in previous evidence syntheses in this area 
[34, 36, 38].
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Nineteen studies were included with data from 833 
participants. The most common modality of interven-
tion delivery across trials was group (n = 9) or individual 
therapy (n = 8), with two trials using a combination of 
these approaches. Some degree of consistency was appar-
ent in the duration of intervention across trials, with the 
modal number being 16 sessions. All studies reported the 
use of CBT protocols that had been adapted for use with 
autistic youth. Most included parent and or clinician rat-
ings of anxiety, with 13 also including self-rating by the 
child/young person. Interestingly, a wide range of assess-
ments were used to profile symptoms of anxiety, but not 
all have support for their use in ASD trials [61, 62] or 
at least not without modifications to allow more robust 
interpretation. Building more consensus on the psycho-
metric soundness and necessary adaptions to measure 
anxiety as an endpoint in ASD will be important as more 
trials emerge. Notably, none of the trials included health 
economic evaluation, despite this forming an important 
framework for assessing value in health interventions 
[63].
The current meta-analyses confirm the efficacy of CBT 
in reducing anxiety in autistic youth, and thus concurs 
with previous reviews [34, 36, 38], and clearly estab-
lishes that effect sizes vary markedly across informants. 
For clinician ratings, which were blind, we found a large 
effect (g = 0.88) versus a moderate effect for parent rated 
symptoms (g = 0.58), although the latter reduced follow-
ing the removal of one extreme outlier (g = 0.42). For 
child/self-rated symptoms, we found a small to moder-
ate effect (g = 0.47), which again reduced after removal of 
one extreme outlier (g = 0.25). A direct analysis in 6 tri-
als using all three informant ratings confirmed a larger 
effect size for clinicians (g  =1.71 [0.66–1.69]) than for 
both parents (g =  0.58 [0.24–0.91]) and the self-ratings 
of children, with the latter being non-significant (g = 0.26 
[− 0.01 to 0.53]) in this sub-analysis.
Turning to factors that might moderate the efficacy of 
CBT, we could divide them broadly into those relating to 
the participants, and those relating to the therapy itself. 
Turning to participant variables, meta-regression sug-
gested that the benefits of CBT may be more pronounced 
in younger children. This may suggest better develop-
mental tailoring of intervention protocols, with room to 
enhance therapeutic techniques for older children. Gen-
der was not a significant moderator, although females are 
generally under-represented in autism research, impact-
ing the power of an analysis to detect a true effect. We 
also found no effect for the proportion of those identified 
as having Asperger syndrome or PDD-NOS. Turning to 
effects related to the therapy itself, the duration of CBT 
was not found to be a contributing factor, but this likely 
reflects most trials including a similar number of sessions 
(i.e. 16). Our subgroup comparison of group versus indi-
vidual CBT revealed only one significant advantage for 
individual therapy for clinician ratings; all other inform-
ant rating revealed no differences. The advantage for 
individual therapy for clinician ratings however needs to 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit
Sofronoff  et al., 2005 Ch 0.04 -0.65 0.72
Sofronoff  et al., 2005 Ch+P -0.22 -0.90 0.45
Wood et al., 2009 1.21 0.49 1.92
McNally Keehn et al., 2013 0.91 0.06 1.76
Storch et al., 2013 0.48 -0.11 1.08
White et al., 2013 0.37 -0.40 1.13
McConachie et al., 2014 0.20 -0.49 0.89
Storch et al., 2015 0.09 -0.59 0.78
Wood et al., 2015 0.71 0.02 1.41
Clarke et al., 2016 0.67 -0.07 1.41
Conaughton et al., 2017 0.46 -0.18 1.09
Murphy et al., 2017 -0.44 -1.09 0.21
Luxford et al., 2017 0.57 -0.15 1.30
Cook et al., 2019 0.77 0.06 1.49
Maskey et al., 2019 0.25 -0.50 1.00
Wood et al 2019 Biaca 0.55 0.25 0.86
Wood et al., 2019 CCT 0.35 0.04 0.67
Kilburn et al., 2020 0.38 -0.18 0.93
0.40 0.24 0.56
-1.50 -0.75 0.00 0.75 1.50
Favours Control Favours CBT
Fig. 2 Forest plot of parent-rated measures of anxiety (minus Chalfant et al. [46])
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Fig. 3 Forest plot of clinician-rated measures of anxiety
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit
Wood et al., 2009 -0.03 -0.68 0.63
Sung et al., 2011 -0.07 -0.56 0.41
McNally Keehn et al., 2013 0.47 -0.34 1.29
Storch et al., 2013 0.76 0.15 1.37
McConachie et al., 2014 0.04 -0.65 0.73
Storch et al., 2015 -0.12 -0.81 0.57
Wood et al., 2015 -0.09 -0.76 0.59
Clarke et al., 2016 0.70 -0.05 1.44
Conaughton et al., 2017 0.39 -0.24 1.02
Luxford et al., 2017 0.57 -0.09 1.23
Maskey et al., 2019 0.23 -0.51 0.96
Kilburn et al., 2020 0.33 -0.22 0.89
0.25 0.06 0.43
-1.50 -0.75 0.00 0.75 1.50
Favours Control Favours CBT
Fig. 4 Forest plot of child-rated measures of anxiety (minus Chalfant et al. [46])
Table 2 Meta regression moderator analyses
a One trial (Cook et al. [31]) included AD and Aspergers but did not say how many of each
Parent (k = 17) Clinician (k = 11) Child (k = 12)
Age Z = − 1.94, p = .05 Z = − 2.23, p = .025 Z = − 0.46, p = .66
Year of publication Z = 0.71, p = .48 Z = − 1.79, p = .07 Z = 1.19, p = .23
Proportion of males Z = 1.28, p = .20 Z = 0.21, p = .83 Z = 0.58, p = .56
Number of sessions Z = 0.67, p = .50 Z = 0.41, p = .68 Z-1.26, p = .20
Proportion of asperger Z = − 0.71, p = .47
(k = 16)a
Z = − 0.61, p = .54 Z = − 0.85, p = .40
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be interpreted cautiously as it involved just 2 group ver-
sus 7 individual trials.
An important difference between the current meta-
analysis and those of both Ung et  al. [36] and Perihan 
et  al. [34] concerns the fact that the latter both pooled 
data across informant. As with the earlier meta-anal-
ysis by Sukhodolsky et  al. [38], we calculated separate 
effect sizes for different informants (clinician, parent 
and child). In the current larger sample of RCTs (more 
than twice as many), we similarly found large variabil-
ity across informant ratings—with clinicians producing 
a large effect, a moderate effect for parents and a small 
effect for the children/ young people themselves. Fur-
thermore, this informant discrepancy pattern emerged in 
studies using all three informant measures, and so, does 
not reflect inter-trial variability. Informant discrepancies 
have been acknowledged as ubiquitous in research on the 
assessment, development, and treatment of childhood 
problems [64]. Indeed, a meta-analysis of 341 studies 
published between 1989 and 2014 reported low-to-mod-
erate correspondence for cross-informant estimates [65]. 
Rather than being averaged away, informant inconsist-
ency requires careful investigation.
The most notable feature of course is the large effect 
size reported for clinicians and the fact that the children/
young people themselves report little or no reduction 
of anxiety following CBT. The clinician and self-ratings 
reported here also differ in one other critical manner and 
that is that all clinician ratings were made blind. Argu-
ably, blinded clinician ratings reporting greater symptom 
improvement might reflect the ability of skilled profes-
sionals to unpick the overlap of anxiety symptoms from 
features of autism per se, though this distinction is a 
source of debate [66]. Our finding of a much larger effect 
size for blinded outcome assessment runs counter to the 
more typical finding that non-blind assessment inflates 
effect sizes [67] and further raises important questions 
about how we assess and who assesses outcome in this 
group and what constitutes a meaningful gain. Given that 
the children/young people themselves are reporting little 
change in their anxiety, it might be tempting to think that 
either they are reluctant or somehow unable to identify 
their anxiety and that the adult ratings are more accurate. 
Informant discrepancies are likely to be greater for inter-
nalising (such as anxiety and mood) over externalising 
mental health concerns (such as aggression and hyper-
activity) [68]. However, the difference between the two 
sets of adult raters (clinicians and parents) was just as 
large; and it does seem as though clinicians are producing 
much greater effect sizes than either parents or children.
The lack of consensus on the ‘gold standard’ measure of 
anxiety for autistic youth [61] adds nuances in interven-
tion research where different assessment tools are used 
across studies and vary in relevance. For example, the 
Spence Children’s Anxiety Scale-Parent Version (SCAS-
P) [57] was used in several studies within our review. 
Table 3 Risk of bias for included studies
Study (date) Selection bias Performance 
bias
Attrition bias Detection bias Reporting bias Overall bias
Sofronoff et al. [41] Low Low Low High Some concerns High
Chalfant et al. [46] Low Low High High Some concerns Some concerns
Wood et al. [47] Low Low Low High Some concerns Some concerns
Sung et al. [48] Low Low Low Low Some concerns Some concerns
Reavan et al. [30] Low Low Low Low Some concerns Some concerns
McNally Keehn et al. [49] Low Low Low Low Some concerns Some concerns
Storch et al. [27] Low Low Low Low Some concerns Some concerns
White et al. [50] Some concern Low Low Low Some concerns Some concerns
McConachie et al. [51] Low Low Low Low Low Low
Storch et al. [52] Low Low Low Low Low Low
Wood et al. [26] Low Low Low Low Low Low
Clarke et al. [53] Low Low Low Low Some concerns Some concerns
Conaughton et al. [28] Low Low Low Low Some concerns Some concerns
Luxford et al. [54] Low Low Low High Some concerns High
Murphy et al. [55] Low Low Low Low Some concerns Some concerns
Cook et al. [31] Low Low Low High Low High
Maskey et al. [56] Low Low Some concerns Low Some concerns Some concerns
Wood et al. [42] Low Low Low Low Some concerns Some concerns
Kilburn et al. [29] Low Low Low Low Low Low
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It has been suggested that whilst this scale is useful, it 
requires adaptation when applied to children on the 
autism spectrum. Using the SCAS-P in its original form 
has been questioned [62, 69], for example, owing to per-
ceived non-applicability of items and the psychometric 
structure of the scale differing. Similarly, for self-rated-
symptoms, engagement requires items to be relevant 
and the informant to have the degree of language and 
cognitive skills to accurately complete [61]. The corre-
lation between parent and child ratings on the Spence 
Children’s Anxiety Scale are favourable for children in the 
general population, whereas ASD parent–child reports 
are typically poorly correlated [70]. Of course, it may be 
that measures developed for youth in the general popu-
lation have comparable sensitivity, specificity, and fac-
tor structure when employed in autistic youth [71] and 
discrepancies reflect real differences. There are two ways 
to explore these assertions further. The first is for future 
trials to utilise measures of parent and self-report anxi-
ety that are developed specifically for autistic youth. Such 
measures should offer a more relevant and reliable pro-
file of symptoms by informants. For example, the 25-item 
Parent Reported Anxiety Scale (PRAS-ASD) [72] or the 
anxiety scale for children with autism spectrum disorder 
(ASC-ASD) [73]. We also advocate qualitative follow-
up in trials to uncover how youth and parents describe 
intervention benefits. This would further insights into 
mechanistic elements, and crucially, offer explanations as 
to why differences exist between the informants of anx-
ious symptoms.
Where outcome reporting beyond post-treatment 
effects was included in trials, we restricted our analy-
ses to studies that did this consistently (i.e. control par-
ticipants included). Although we identified 23 sets of 
follow-up data from various informant groups, only 8 
followed-up the control group and these all came from 5 
trials. This resulted in synthesis of parent and child rated 
anxiety only and yielded no support for sustained treat-
ment effects at follow-up (range 1–9  months). Whilst 
data from studies in the general population have sup-
ported the long-term effectiveness of CBT for anxiety in 
youth [74], we might expect different end states for youth 
on the autism spectrum where other daily-challenges 
could interfere with ratings of overall quality of life [61]. 
Given the small numbers of trials with follow-up data, 
we would apply some caution in interpreting. Nonethe-
less, parents, providers and service commissioners in 
particular will benefit from knowing the extent to which 
CBT facilitates lasting improvement in functioning; and 
such information will help set expectations for families. 
By identifying predictors of sustained gain versus relapse, 
clinicians might also be able to better optimise treatment 
protocols and so future trials need to attend to this.
Some caveats need to be acknowledged when inter-
preting the current findings. The first relates to the 
assessment of risk of bias, which had not been examined 
in the three previous meta-analyses [34, 36, 38]. Only 
three trials were at low risk of bias, with the majority hav-
ing ‘some concern’ and three studies were rated as at high 
risk of bias, mostly due to ‘reporting bias’. As the field of 
clinical trials advances further, the requirement to pro-
spectively register study protocols should address the 
lack of clarity around whether trials have selectively pub-
lished outcomes. Reporting bias is under-recognised and 
impacts on the interpretation of findings from clinical 
trials [75]. Second, the large amount of heterogeneity in 
studies including clinician ratings could not be explained 
by the moderator analyses undertaken. This has made 
it difficult to explain treatment effects with available 
information about study and participant characteristics. 
The added detection of publication bias in these studies 
should also be viewed with caution. Third, we are una-
ble to make any definitive conclusions about sustained 
improvement in symptoms beyond posttreatment effects 
because of the small numbers of studies analysed. It will 
be important for future trials to include this data so that 
durability of intervention gains can be fully explored. 
Most studies included in this meta-analysis also had 
small samples (the mean receiving CBT was 23 and con-
trols 18) and were underpowered to detect even the larg-
est effect size reported for clinicians. The current results 
suggest that the optimal number will vary depending 
upon which informant ratings are taken from. Finally, we 
acknowledge that our own review was not pre-registered, 
though all data have been made available with details of 
the search results itself (i.e. Fig. 1).
Conclusions
This study provides the largest meta-analysis (19 RCTs 
and 833 participants) to date on the efficacy of CBT for 
anxiety in children and adolescents on the autism spec-
trum. Our primary findings concur with previous reviews 
showing that CBT reduces anxiety in the immediate 
posttreatment period. Indeed, ratings by all three inform-
ant types were consistent in documenting a significant 
reduction of anxiety; and showed little or no evidence of 
publication bias. Nevertheless, the substantial variabil-
ity in effect sizes across clinicians, parents and children 
would advise against future meta-analyses pooling across 
informants. It is notable that risk of bias was low except 
in the domain of reporting bias, where risk was generally 
higher. The latter seems to reflect the lack of preregistra-
tion of trials.
Recommendations for future trials include a focus on 
selecting autism-specific measures of anxiety or at least 
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making necessary adaptions to scales; prospective regis-
tration of trials to overcome potential reporting biases; 
and the inclusion of follow-up analyses to assess whether 
treatment gains are sustained. We also note the absence 
of reporting on adverse events and the relative absence of 
health economic evaluation across trials, both of which 
are crucial to determine the wider value of the interven-
tion beyond the reduction of symptomatology.
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